Tags : Emergent BioSolutions

Insights+: COVID-19 Healthcare News Monthly Updates – August 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

Insights+: COVID-19 Healthcare News Monthly Updates – July 2020

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

AstraZeneca Signs an Agreement with Emergent BioSolutions to Expand Manufacturing

Shots: Emergent will provide CDMO services for AstraZeneca’ AZD1222. The agreement valued ~174M through 2021 and follows an $87M agreement signed in June for development services, performance and process qualification, raw materials, and an initial capacity reservation The two companies may enter additional commercial manufacturing agreement as the candidate progresses over three years through Emergent’s […]Read More

Insights+ COVID-19 Deals (Part II): Biopharma Vaccine Development

The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies, as well as government agencies, to partner at unprecedented speed to develop vaccines, treatments, and tests.  This article covers the last four months of deal data provided by Chris Dokomajilar of DealForma. During the last four months […]Read More

Janssen Collaborates with Emergent BioSolutions to Accelerate the Manufacturing of

Shots: Janssen partnered with Emergent to develop more than a billion doses of a COVID-19 vaccine candidate, as it anticipates scaling up global manufacturing of its potential treatment. The agreement valued ~135M Emergent will provide manufacturing services with its molecule-to-market CDMO offering, beginning in 2020 and will reserve operations capacity to support manufacturing of J&J’s […]Read More